

**IN THE UNITED STATES DISTRICT COURT FOR THE
NORTHERN DISTRICT OF ILLINOIS**

JEROME FINNIGAN, and

JANE FINNIGAN

Plaintiff,

Case No.:

vs.

NOVO NORDISK INC., and

NOVO NORDISK A/S,

Defendant,

_____ /

COMPLAINT AND JURY DEMAND

COMES NOW, Plaintiff(s), JEROME FINNIGAN and JANE FINNIGAN, by and through the undersigned counsel, and brings this complaint against Defendant Novo Nordisk Inc. and Novo Nordisk A/S for damages suffered by JEROME FINNIGAN who was severely injured as a result of Defendant's widespread marketing of their drug, Ozempic, and his subsequent use of Ozempic, an injectable prescription medication for improvement of blood sugar (glucose) in adults with type 2 diabetes and heavily prescribed for weight loss, and alleges as follows:

PARTIES, JURISDICTION AND VENUE

1. At all relevant times hereto, Plaintiff, Jerome Finnigan, was a resident and citizen of the state of Illinois.

2. Plaintiff was prescribed and took Ozempic as directed by his physicians. As a result of his use of Ozempic, he has lost vision in his right eye and experienced loss of peripheral vision secondary to the development of Non-arteritic Anterior Ischemic Optic

Neuropathy (NAION) and suffers severe physical and emotional injuries and radical changes to his lifestyle given his severe loss of sight.

3. Novo Nordisk Inc. (“Novo Nordisk”) is a Delaware corporation that has its principal place of business at 800 Scudders Mill Road, Plainsboro, New Jersey 08536.

4. Novo Nordisk A/S is the parent corporation that has its principle place of business at Novo Alle, 2880 Bagsvaerd, Denmark.

5. Defendant Novo Nordisk Inc. is wholly owned by Novo Nordisk US Commercial Holdings, Inc.

6. Upon information and belief, Defendant failed to warn physicians and the end users of Ozempic of the complications and devastating effects of which the company knew or should have known, including NAION, which can result in blindness and permanent vision loss.

7. Upon information and belief, Defendant’s marketing was deceptive and misleading about the true risks associated with use of Ozempic of which the company knew or should have known.

BACKGROUND

I. The Development and Approval of Ozempic

7. In the early 1990s, Novo Nordisk researchers discovered that when they injected into rats a chemical compound known as liraglutide—a GLP-1 (glucagon-like peptide-1) agonist—the drug caused the rats to stop eating almost entirely.¹

8. GLP-1 agonists are a class of medications that can help lower blood sugar levels and promote weight loss.² An agonist is a manufactured substance that attaches to a cell receptor and

¹ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited Feb. 13, 2025).

² <https://my.clevelandclinic.org/health/articles/13901-glp-1-agonists> (last visited Feb. 13, 2025)

causes the same action as the naturally occurring substance.³ Thus, GLP-1 agonists work by mimicking a naturally occurring GLP-1 hormone.

9. To describe the process in other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles) of the GLP-1 hormone. The higher the dose of the GLP-1 agonist, the more extreme the effects.⁴

10. “These rats, they starved themselves,” said one Novo Nordisk scientist, Lotte Bjerre Knudsen, in a video series released by the Novo Nordisk Foundation, “so we kind of knew there was something in some of these peptides that was really important for appetite regulation.”⁵

11. Later testing in human subjects revealed that those who received an intravenous drip of GLP-1 agonist ate 12% less at a lunch buffet than those who got a placebo.⁶

12. Consequently, Novo Nordisk decided to study liraglutide as not only a diabetes drug which had been shown to lower blood sugars, but also as a drug to treat obesity.⁷

13. Years later, in 2010, liraglutide was approved for the treatment of diabetes by the FDA under Novo Nordisk's brand name Victoza,⁸ at which point Novo Nordisk moved forward with studying the drug for weight loss.⁹

14. After clinical trials, in 2014 the FDA approved liraglutide for treatment of obesity under Novo Nordisk's brand name Saxenda as a daily injectable.¹⁰

³ *Id.*

⁴ *Id.*

⁵ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited Feb. 13, 2025).

⁶ *Id.*

⁷ *Id.*

⁸ Jackson, S. H., Martin, T. S., Jones, J. D., Seal, D., & Emanuel, F. (2010). Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. *P & T: a peer-reviewed journal for formulary management*, 35(9), 498–529. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2957743/> (last visited Feb. 13, 2025).

⁹ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited Feb. 13, 2025).

¹⁰ *Id.*

15. Saxenda's effects on weight loss, however, were modest; patients lost about 5% of their weight.¹¹

16. In an effort to find ways to make a longer-lasting GLP-1 agonist so patients would not have to inject themselves every day, Novo Nordisk created a new molecule with the chemical name semaglutide.¹²

17. Novo Nordisk branded semaglutide as Ozempic, and on December 5, 2016 announced submission of Ozempic's New Drug Application (NDA) to the FDA for regulatory approval of once-weekly injectable in 0.5 mg or 1 mg for treatment of type 2 diabetes. The announcement stated "once-weekly" Ozempic had a safe and well-tolerated profile, and that the most common adverse event was nausea.¹³

18. On December 5, 2017, the FDA approved the application and granted premarket approval as NDA 209637 to Defendant Novo Nordisk Inc.¹⁴

19. Defendant continues to be the holder of the NDA and therefore is required to submit supplements to the NDA, complete post-marketing surveillance, submit adverse event reports, maintain correspondence with the FDA and update the label.

20. Just one year after Ozempic's approval for diabetes, Defendant started a clinical trial in patients who were overweight or suffered from obesity.¹⁵

21. Defendant had completed the clinical trial studying semaglutide for weight loss, and its results were published February 10, 2021.¹⁶

¹¹ *Id.*

¹² *Id.*

¹³ <https://ml.globenewswire.com/Resource/Download/d2f719e1-d69f-4918-ae7e-48fc6b731183> (last visited Feb. 13, 2025).

¹⁴ https://www.accessdata.fda.gov/Ozempicatfda_docs/appletter/2017/209637s000ltr.pdf (last visited Feb. 13, 2025).

¹⁵ *Id.*

¹⁶ Wilding John P.H., Batterham Rachel L., Calanna Salvatore, et al. Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

22. In addition to the results, the published study, which was funded by Defendant, argued: “Obesity is a chronic disease and global public health challenge.”¹⁷

23. On March 20, 2019, Defendant Novo Nordisk Inc. submitted supplemental a new drug application for Ozempic 0.5 mg or 1 mg injection, requesting approval to expand its marketing of Ozempic by adding an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.¹⁸ On January 16, 2020, the FDA approved this new indication.¹⁹

24. Then, on May 28, 2021, Defendant Novo Nordisk Inc. submitted another sNDA requesting approval for a higher 2 mg dose of Ozempic injection. On March 28, 2022, the FDA approved this request.²⁰

25. In their press release, Defendant represented Ozempic as having “proven safety and efficacy,” and they continued to advertise that “it can help many patients lose some weight.”²¹ As with its prior press releases, Defendant disclosed Important Safety Information and provided a link to the Medication Guide and Prescribing Information. However, NAION and permanent vision loss were not identified as risks.

II. Marketing and Promotion Create a Media Frenzy and Mega Seller

26. Since Defendant discovered GLP-1 agonists potential use for weight loss, Defendant began working to change medical consensus as it relates to obesity.

¹⁷ *Id.*

¹⁸ <https://www.prnewswire.com/news-releases/novo-nordisk-files-for-us-fda-approval-of-oral-semaglutide-for-blood-sugar-control-and-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-300815668.html> (last visited on Feb. 13, 2025).

¹⁹ https://www.accessdata.fda.gov/Ozempicatfda_docs/applletter/2020/209637Orig1s003ltr.pdf (last visited Feb. 13, 2025).

²⁰ https://www.accessdata.fda.gov/Ozempicatfda_docs/applletter/2022/209637Orig1s009ltr.pdf (last visited Feb. 13, 2025).

²¹ <https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-higher-dose-ozempic-2-mg-providing-increased-glycemic-control-for-adults-with-type-2-diabetes-301512209.html> (last visited Feb. 13, 2025).

27. Throughout their marketing, Defendant fails to disclose the true serious side effects of Ozempic, such as permanent vision loss.

28. When the Defendant announced that they had started selling Ozempic in the United States, they touted the medication as a “new treatment option[.]” that “addresses the concerns and needs of people with diabetes[.]” The Defendant offered an “Instant Savings Card to reduce co-pays to as low as \$25 per prescription fill for up to two years.”

29. Novo Nordisk was not permitted to market Ozempic for weight loss without FDA approval for that specific indication,²² but Novo Nordisk had already begun mentioning weight loss in their Ozempic commercials.²³

30. On July 30, 2018, the Defendant launched its first television ad for Ozempic with the catchy jingle to the tune of the 1970s hit pop song “Magic” by Pilot, wherein the Defendant advertised that “adults lost on average up to 12 pounds” when taking Ozempic.²⁴

31. Over the next five years, the Defendant spent 884,000,000 million dollars on running television ads in the United States to promote its semaglutide Ozempic, Wegovy, and another of its lesser known GLP-1 agonists, Rybelsus, with most advertisements allocated towards Ozempic.²⁵

32. Defendant’s aggressive marketing includes a number of different platforms, including over 4,000 marketing advertisements for Ozempic and similar weight-loss medications that have been placed on Facebook and Instagram.²⁶

33. As a result of this heavy focus on direct-to-consumer advertising, many patients

²² <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited Feb. 13, 2025).

²³ *Id.*

²⁴ <https://www.ispot.tv/ad/d6Xz/ozempic-oh> (last visited Feb. 13, 2025).

²⁵ https://medwatch.com/News/Pharma_Biotech/article15680727.ece (last visited Feb. 13, 2025).

²⁶ <https://www.nbcnews.com/tech/internet/ozempic-weight-loss-drug-ads-instagram-wegovy-semaglutide-rcna88602> (last visited Feb. 13, 2025).

specifically sought out prescriptions for Ozempic.

34. According to open payments data, Novo Nordisk spent \$33,927,336.42 on marketing/consulting/travel/food and beverage/etc. to physicians in 2022 alone.²⁷

35. Novo Nordisk partnered directly with Meta and Instagram to run marketing campaigns. One diabetes marketing campaign achieved a dramatic 28% direct engagement rate with their polls.²⁸

36. On July 10, 2023, a global media company declared Ozempic as “2023’s buzziest drug” and one of the “Hottest Brands, disrupting U.S. culture and industry.”²⁹

37. Novo Nordisk reportedly spent approximately one hundred million dollars advertising Ozempic in 2022.³⁰ Ozempic ranked as the sixth most-advertised prescription drug brand in 2022, with a U.S. measured-media spend of \$181 million, according to Vivvix spending data and Pathmatics paid social data as reported in Ad Age Leading National Advertisers 2023.³¹

38. In 2023, over \$491 million was spent advertising “diabetesity” drugs, including Ozempic.³²

39. Defendant also owns and operates several marketing campaign websites that are created for the purposes of educating on the science of obesity and creating a change in how obesity is understood and treated.

40. This includes the website “The Truth about Weight.”³³

²⁷ <https://openpaymentsdata.cms.gov/company/100000000144> (last visited Feb. 13, 2025).

²⁸ <https://business.instagram.com/success/novo-nordisk> (last visited Feb. 13, 2025).

²⁹ <https://adage.com/article/special-report-hottest-brands/ozempic-hottest-brands-most-popular-marketing-2023/2500571> (last visited on Feb. 13, 2025).

³⁰ <https://www.newyorker.com/magazine/2023/03/27/will-the-ozempic-era-change-how-we-think-about-being-fat-and-being-thin> (last visited Feb. 13, 2025).

³¹ https://adage.com/article/special-report-hottest-brands/ozempic-hottest-brands-most-popular-marketing-2023/2500571?utm_source=exchange&utm_medium=email&utm_campaign=t5687390 (last visited Feb. 13, 2025).

³² <https://www.mmm-online.com/home/channel/spending-on-ozempic-wegovy-surges/> (last visited Feb. 13, 2025).

³³ Truth About Weight, <https://www.truthaboutweight.com/> (last visited on Feb. 13, 2025).

41. Defendant has also spent significant resources aligning themselves and infiltrating their influence into physician and advocacy groups.

42. This includes the American Board of Obesity Medicine. The former Director of the American Board of Obesity Medicine who served from 2017 to November of 2021 received payments by Novo Nordisk during her time as director of the American Board of Obesity Medicine.³⁴

43. This former director of the American Board of Obesity Medicine currently promotes their GLP-1 agonists for weight loss as part of their telehealth company and continues to receive payments.³⁵

44. At least one member of the American Board of Obesity Medicine that helped write the guidelines for obesity management has received payments directly from Novo Nordisk according to Open Payments Data during the same time he wrote those guidelines.³⁶

45. Novo Nordisk contributes money directly to education courses used to satisfy continuing education requirements or to prepare for certification in obesity medicine.³⁷

46. Novo Nordisk serves on the board and/or provides direct financial contributions to many public health advocacy groups.

47. This includes Obesity in Action Coalition, to which Novo Nordisk contributes more than \$500,000 annually.³⁸ Novo Nordisk has been a partner since 2013, before any of its drugs

³⁴<https://joinfound.com/pages/medication-biology> (last visited on Feb. 14, 2025); <https://openpaymentsdata.cms.gov/physician/1294300> (last visited Feb 14, 2025); <https://www.linkedin.com/in/rekha-kumar-m-d-m-s-70b481237/> (last visited on Feb. 14, 2025).

³⁵<https://joinfound.com/pages/medication-biology> (last visited on Feb. 14, 2025); <https://openpaymentsdata.cms.gov/physician/1294300> (last visited on Feb. 14, 2025); <https://www.linkedin.com/in/rekha-kumar-m-d-m-s-70b481237/> (last visited on Feb. 14, 2025).

³⁶<https://openpaymentsdata.cms.gov/physician/1379381> (last visited Feb. 14, 2025); see also <https://www.abom.org/karl-nadolsky/>.

³⁷ *Id.*

³⁸ <https://www.obesityaction.org/corporate-partners/> (last accessed Feb. 14, 2025).

were approved for weight loss.

48. Novo Nordisk also serves on the Corporate Council of American Society for Metabolic and Bariatric Society, another public health partner of the American Board of Obesity Medicine.³⁹

49. Novo Nordisk is also a corporate member and directly financially contributes to Stop Obesity Alliance, yet another public health partner of the American Board of Obesity Medicine.⁴⁰

50. Novo Nordisk is a member of additional advocacy organizations and lobbying groups separate and apart from these public health partners of the American Board of Obesity Medicine.

51. This includes the Obesity Care Advocacy Network, which lobbies for legislation to expand access to Novo Nordisk's drugs.⁴¹

52. Defendant has deceptively promoted their weight loss drugs on television and news segments.

53. For example, Novo Nordisk's drugs were the subject of an investigative report on 60 Minutes that aired New Year's Day of 2023.⁴²

54. Complaints have been filed alleging that the "news" piece was in reality "deceptive marketing" in which all physicians interviewed had received payments by Novo Nordisk.⁴³

55. The financial relationship between the physicians speaking about Ozempic and

³⁹ <https://asmb.org/corporate-council> (last visited Feb. 14, 2025).

⁴⁰ <https://stop.publichealth.gwu.edu/membership> (last visited on Feb. 14, 2025).

⁴¹ https://assets.obesitycareadvocacynetwork.com/TROA_fact_sheet_11_12_21_48098432e0/TROA_fact_sheet_11_12_21_48098432e0.pdf (last visited on Feb. 14, 2025)

⁴² <https://www.cbsnews.com/news/wegozy-ozempic-explainer-60-minutes-2023-01-01/> (last visited Feb. 14, 2025).

⁴³ <https://www.fiercepharma.com/marketing/health-group-lambasts-novo-nordisk-60-minutes-paid-news-program-weight-loss-med-wegovy> (last visited Feb. 14, 2025).

Novo Nordisk was not explicitly disclosed.⁴⁴ The reporter stated that the physicians had *advised* Novo Nordisk but failed to state they had been compensated by the company.⁴⁵

56. The FDA is currently investigating the marketing practices of Novo Nordisk.⁴⁶

57. Novo Nordisk has spent millions of dollars delivering their message to physicians, healthcare providers, and consumers.

58. For example, Novo Nordisk spent over \$33,000,000 in 2022 on traditional physician marketing and detailing according to Open Payments Data.⁴⁷

59. Defendant has directly and indirectly partnered with telehealth providers to promote their weight loss drugs.

60. This includes a 2019 direct partnership between Novo Nordisk and Noom, a leading behavior weight loss company.⁴⁸

61. In 2021, Novo Holdings participated in a \$540 million round of financing with Noom.⁴⁹ At that time, Novo Holdings tweeted that it “is pleased to note that it has participated in the \$540 million Series F round in @noom, a leading digital health platform...”.⁵⁰

62. Novo Holdings currently lists on its website that it has “venture investments” in Noom.⁵¹

63. Noom Med now provides to consumers, using physicians hired by Noom,

⁴⁴ <https://fair.org/home/60-minutes-weight-loss-tip-dont-bite-the-hand-that-feeds-you/> (last visited on Feb. 14, 2025).

⁴⁵ *Id.*

⁴⁶ <https://www.pcrm.org/news/news-releases/fda-confirms-investigation-novo-nordisk-ad-posed-60-minutes-story-about-weight> (last visited Feb. 14, 2025)

⁴⁷ <https://openpaymentsdata.cms.gov/company/100000000144> (last visited Feb. 14, 2025)

⁴⁸ <https://www.prnewswire.com/in/news-releases/novo-nordisk-and-noom-to-partner-around-digital-health-solutions-to-help-people-with-obesity-lose-weight-and-keep-it-off-811725389.html> (last visited on Feb. 14, 2025).

⁴⁹ <https://www.businesswire.com/news/home/20210525005492/en/Noom-Announces-540-Million-in-Growth-Funding-to-Further-Accelerate-Expansion-of-its-Digital-Health-Platform>

⁵⁰ <https://twitter.com/novoholdings/status/1397170264702599171>

⁵¹ <https://novoholdings.dk/investments/noom/>

prescriptions for weight loss directly to patients.⁵²

64. Noom Med promotes off label usage of these weight loss drugs on its website.⁵³

65. Noom currently has over 45 million users.⁵⁴

66. Other telehealth providers have jumped on board the bandwagon in offering prescriptions directly to consumers for Defendant's weight-loss medications.

67. This includes Weight Watchers, who purchased telehealth startup Sequence for \$132,000,000 in order to provide weight loss medications to its subscribers.⁵⁵

68. There are currently over 3.5 million Weight Watchers subscribers.⁵⁶

69. It also includes Calibrate, yet another telehealth provider for weight loss medications, which raised \$100 million in capital funding from investors in 2021.

70. Collectively, the telehealth providers that Novo Nordisk directly and indirectly partners with and/or promotes account for approximately half of all weight loss prescriptions in 2022.⁵⁷

71. In sum, Defendant promoted the safety, efficacy, and sale of Ozempic in the United States on its websites, in press releases, through in-person presentations, through the drug's label, in print materials, on social media, advocacy groups, lobbying groups, celebrity partnerships, telehealth partnerships, key opinion leaders, and through other public outlets.

⁵² <https://abcnews.go.com/GMA/Wellness/noom-joins-weight-watchers-offering-medications-wegovy-weight/story?id=99841160> (last visited on Feb. 14, 2025).

⁵³ <https://www.noom.com/med/> (last visited on Feb. 14, 2025).

⁵⁴ <https://exitsandoutcomes.com/free-excerpt-from-the-noom-report-a-45-million-moat/> (Feb. 14, 2025).

⁵⁵ <https://www.usatoday.com/story/news/health/2023/03/07/weightwatchers-sequence-wegovy-obesity-weight-loss-drugs/11415201002/> (last visited on Feb. 14, 2025).

⁵⁶ <https://finance.yahoo.com/news/ww-international-inc-announces-first-200100340.html#:~:text=%E2%80%9CWe%20expect%20to%20end%202023,including%203.5%20million%20WeightWatchers%20subscribers> (last visited on Feb. 14, 2025).

⁵⁷ <https://www.statnews.com/2023/08/10/wegovy-ozempic-weight-loss-telehealth-prescriptions/>

72. Novo Nordisk's comprehensive, immersive marketing has left no stone unturned in delivering their message that physicians and patients must use their drugs to treat obesity.

III. Marketing Works: Defendant's Rampant Promotion Result in Thousands of Prescriptions and Billions in Sales

73. As a result of Defendant's all-encompassing advertising and promotion efforts, Ozempic are widely prescribed throughout the United States.

74. In July of 2021, doctors in the US wrote 62,000 prescriptions a week for Ozempic.⁵⁸

75. It has been reported that the huge demand created by extensive marketing has led to rampant off-label usage and "gaming" the system to allow for insurance coverage.⁵⁹

76. The number of prescriptions filled reached an all-time high of 373,000 in one week in February of 2023, with more than half of those being new prescriptions.⁶⁰

77. In June 2023, it was reported that new prescriptions for Ozempic had surged by 140 percent from the prior year.⁶¹

78. As of August 10, 2023, Novo Nordisk reported that in the first six months of 2023 sales of Ozempic jumped 50% in the U.S. to more than \$3.7 billion.⁶²

IV. Use of Ozempic has been linked to the development of NAION

79. The Defendant knew or should have known of the risk of NAION with use of Ozempic.

⁵⁸ <https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html> (last visited on Feb. 14, 2025)

⁵⁹ *Id.*

⁶⁰ <https://www.cnn.com/2023/03/17/health/ozempic-shortage-tiktok-telehealth/> (last visited on Feb. 14, 2025).

⁶¹ <https://www.washingtonpost.com/business/2023/06/11/weight-loss-ozempic-wegovy-insurance/> (last visited on Feb. 14, 2025).

⁶² <https://www.cnbc.com/2023/09/09/big-pharma-blockbuster-obesity-drug-battle-is-headed-for-100-billion.html#:~:text=Novo%20traded%20earnings%20jabs%20with,to%20more%20than%20%243.7%20billion.> (last visited Feb. 14, 2025).

80. Defendant conducts clinical trials and has access to case reports and medical literature that provides them with superior knowledge compared to the general public as to the potential risks of their medications.

81. For example, in a clinical trial entitled “A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN FORTE)” with results first submitted in August 2021, involved a participant who developed optic ischemic neuropathy which was categorized as a serious adverse event.⁶³

82. The event occurred within the Semaglutide 2.0 mg dosage group which included 479 participants which is significant given the low background incidence of NAION.⁶⁴

83. Non-arteritic anterior ischemic optic neuropathy (NAION) is a medical condition involving damage to the optic nerve resulting in the loss of vision.

84. It falls within the category of an eye stroke.

85. While the precise cause of NAION is unknown, the general belief amongst the medical community is that the condition is caused by insufficient blood supply or ischemia to the optic nerve.

86. “[T]ransient hypoperfusion of the short posterior ciliary arteries causes acute ischemia to the optic nerve head (ONH), resulting in axonal swelling. This swelling compromises the axoplasmic flow, which subsequently increases the axonal swelling, contributing to the compression of ONH microcirculation, exacerbating the ischemia.”⁶⁵

⁶³ A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN FORTE). ClinicalTrials.gov identifier: NCT03989232. Updated February 13, 2023. Accessed February 18, 2025.

⁶⁴ *Id.*

⁶⁵ Wu, Kevin Yang and Evoy, François NAION: Diagnosis and Management. American Academy of Ophthalmology. August 1, 2022. Accessed February 18, 2025. <https://www.aao.org/eyenet/article/naion-diagnosis-and-management>

87. Anterior ischemic optic neuropathy (AION) involves the 1mm segment of the optic nerve head, also known as the optic disc, and results in visible disc swelling.⁶⁶

88. Typically, NAION patients present with acute, painless vision loss in one eye that is often described as blurry or cloudy while 8-12% of patients may have accompanying pain such as a headache or periocular pain.⁶⁷

89. The vision loss may occur over hours to days, but generally NAION patients notice vision loss or even total blindness upon waking in the morning.⁶⁸

90. Unfortunately, there is no effective treatment for NAION. Vision may worsen in the four weeks following the event. Some patients may see modest improvement in their vision, but complete recovery of vision is unusual.⁶⁹

91. After glaucoma, NAION is the second most common cause of blindness due to optic nerve damage.⁷⁰

92. Some NAION patients lose complete vision with no recovery in affected eye(s).

93. Reduced or loss of vision has a detrimental impact on a person's day-to-day life. Many NAION patients cannot drive or have driving restrictions, cannot read or have trouble reading, and may be unable to continue in their line of employment. Being blinded in one eye and certainly both eyes results in bumps and falls and injuries related to the unseen impacts and accidents.

⁶⁶ Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). American Academy of Ophthalmology, EyeWiki. [https://eyewiki.org/Non-Arteritic_Anterior_Ischemic_Optic_Neuropathy_\(NAION\)](https://eyewiki.org/Non-Arteritic_Anterior_Ischemic_Optic_Neuropathy_(NAION)). Accessed February 18, 2025.

⁶⁷ *Id.*

⁶⁸ *Id.*

⁶⁹ Wu, Kevin Yang and Evoy, François NAION: Diagnosis and Management. American Academy of Ophthalmology. August 1, 2022. Accessed February 18, 2025. <https://www.aao.org/eyenet/article/naion-diagnosis-and-management>

⁷⁰

94. GLP-1 receptors have been detected in neuronal cells in the human eye.⁷¹

95. Clinical observations by astute neuro-ophthalmologists at the Harvard affiliated Massachusetts Eye and Ear (“Mass Eye and Ear”) who noted a surge of NAION cases amongst patients on Ozempic led them to conduct a retrospective, matched cohort study of neuro-ophthalmic patients at Mass Eye and Ear, Boston.

96. The study “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide” authored by Hathaway *et al.* involved patients examined in the neuro-ophthalmology clinic between December 1, 2017 and November 30, 2023 and consisted of 17,298 patients including 16,827 patients over the age of 12, 710 of which had type 2 diabetes (T2D) and 979 were overweight or obese.⁷²

97. Of the 710 T2D patients, 194 patients were prescribed semaglutide and 516 were prescribed other non-GLP-1 RA antidiabetic medications.⁷³

98. Of the 979 overweight/obese patients, 361 were prescribed semaglutide and 618 were prescribed other non-GLP-1 RA anti-obesity medications.⁷⁴

99. Within the T2D study population, NAION occurred in 17 patients in the semaglutide cohort vs. 6 in the non-GLP-1 RA cohort. The Kaplan-Meier survival analysis at 36 months showed a cumulative incidence of NAION of 8.9% (95% CI, 4.5%-13.1%) for the semaglutide cohort vs 1.8% (95% CI, 0%-3.5%) for the nonsemaglutide cohort and the Cox proportional hazards regression model showed a higher NAION risk in the semaglutide cohort vs

⁷¹ Hebsgaard JB, Pyke C, Yildirim E, Knudsen LB, Heegaard S, Kvist PH. Glucagon-like peptide-1 receptor expression in the human eye. *Diabetes Obes Metab.* 2018; **20**(9): 2304-2308. doi:10.1111/dom.13339

⁷² Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. *JAMA Ophthalmol.* 2024;142(8):732–739. doi:10.1001/jamaophthalmol.2024.2296

⁷³ *Id.*

⁷⁴ *Id.*

the nonsemaglutide cohort (HR, 4.28; 95% CI, 1.62-11.29; $P < .001$; concordance coefficient = 0.84).⁷⁵

100. Within the overweight/obese cohort, NAION occurred in 20 patients in the semaglutide cohort vs. 3 in the non-GLP-1 RA cohort. The Kaplan-Meier survival analysis at 36 months showed a cumulative incidence of NAION of 6.7% (95% CI, 3.6%-9.7%) for the semaglutide cohort vs 0.8% (95% CI, 0%-1.8%) for the nonsemaglutide cohort and the Cox proportional hazards regression model showed a higher NAION risk in the semaglutide cohort vs the nonsemaglutide cohort (HR, 7.64; 95% CI, 2.21-26.36; $P < .001$; concordance correlation coefficient = 0.86).⁷⁶

101. The primary outcome of the Hathaway *et al.* study is that use of Ozempic is associated with an increased risk of NAION. “The relatively high HRs (4.28 and 7.64 for our T2D and overweight or obese cohorts, respectively) identified by our Cox regression analyses reveal a substantially increased risk of NAION among individuals prescribed semaglutide relative to those prescribed other medications to treat T2D and obesity or overweight.”⁷⁷

102. Acknowledging the pathogenesis or cause of NAION remains unknown, the authors did not determine the mechanism in which semaglutide causes NAION, however, it was hypothesized that expression of the GLP-1 receptor in the optic nerve and GLP-1 RA–induced enhanced sympathetic nervous system activity might influence optic nerve head perfusion and potentially increase the risk of NAION.⁷⁸

103. A metanalysis of all clinical trials of GLP-1 receptor drugs, including Novo’s own

⁷⁵ *Id.*

⁷⁶ *Id.*

⁷⁷ *Id.*

⁷⁸ *Id.*

clinical trials, found a non-statistically increased risk of optic ischemic neuropathy.⁷⁹ Because optic ischemic neuropathy is rare, the authors note there may have been underreporting in the clinical trials, leading a lower estimated risk.⁸⁰ However, the study concluded the overall rate of optic ischemic neuropathy was higher in the GLP1-RA group compared to the placebo group: 5.6 and 3.0 cases per 100,000 patient-years, respectively which is nearly a doubling of the risk.⁸¹

104. On December 11, 2024, a pre-print of an article entitled “Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish- Norwegian cohort study”, found an association between use of semaglutide for type 2 diabetes.⁸²

105. This cohort study compared the risk of NAION among individuals with type 2 diabetes using semaglutide compared to those using sodium-glucose co-transporter 2 inhibitors (SGLT-2s), another diabetes medication.⁸³ The authors concluded there is “an association between use of semaglutide for type 2 diabetes and risk of NAION, with a more than two-fold increased hazard ratio.”⁸⁴

106. In a registry-based prospective cohort study identifying 424,152 patients diagnosed with type 2 diabetes in Denmark between December 1, 2018 and December 31, 2023,⁸⁵ 106,454 of these patients were exposed to semaglutide and 67 developed NAION.⁸⁶

⁷⁹ Silverii GA, Pala L, Cresci B, Mannucci E. Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials. *Diabetes Obes Metab.* 2025; 27(2): 1005-1009. doi:[10.1111/dom.16076](https://doi.org/10.1111/dom.16076)

⁸⁰ *Id.*

⁸¹ *Id.*

⁸² Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study. Published online December 11, 2024. doi:[10.1101/2024.12.09.24318574](https://doi.org/10.1101/2024.12.09.24318574)

⁸³ *Id.*

⁸⁴ *Id.*

⁸⁵ Grauslund J, Taha AA, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. *Intl. Journal of Retina and Vitreous.* 2024;10(1):97. doi:[10.1186/s40942-024-00620-x](https://doi.org/10.1186/s40942-024-00620-x)

⁸⁶ *Id.*

107. “Exposure to once-weekly semaglutide was followed by 67 events of NAION during 294,395 years of observation as compared to 151 events during the 1,620,725 years of observation for non-exposed.”⁸⁷

108. The study concluded use of semaglutide “more than doubles the risk of NAION, even when multiple other factors have been taken into account.”⁸⁸

109. Interestingly, the study also observed that “after the introduction of once-weekly semaglutide in Denmark in November 2018, the annual number of first-time NAION episodes reached an all-time high for the years 2019-2023.”⁸⁹

110. Due to the findings of the two studies out of Denmark, as of January 17, 2025, the Pharmacovigilance Risk Assessment Committee (PRAC) of the Danish Medicines Agency has required Novo Nordisk to review and submit available data related to semaglutide and NAION and that the PRAC will review and determine if a label change is warranted or if other risk minimization efforts should be pursued.⁹⁰

111. In response, Novo Nordisk has acknowledged confirmed cases of NAION were identified within their clinical trials.⁹¹

112. A recent case series published by Katz *et al.*, “Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide,” also examined nine patients taking GLP1-RA medications who had experienced ophthalmologic complications. Of the nine patients, seven developed NAION.⁹²

⁸⁷ *Id.*

⁸⁸ *Id.*

⁸⁹ *Id.*

⁹⁰ <https://laegemiddelstyrelsen.dk/en/news/2024/suspicion-of-rare-eye-condition-from-ozempic-use-to-be-investigated-further/>

⁹¹ <https://www.fiercepharma.com/pharma/novo-nordisk-faces-new-reports-suggesting-link-between-ozempic-and-blindness>

⁹² Katz BJ, Lee MS, Lincoff NS, et al. Ophthalmic Complications Associated With the Antidiabetic Drugs

113. The Katz article included a report of a woman with type 2 diabetes taking insulin and semaglutide and evidence of positive challenge and rechallenge with semaglutide.⁹³

114. The morning after the patient's first injection of semaglutide, she experienced painful vision loss in her left eye and was diagnosed with bilateral optic nerve swelling and the initial impression was optic neuritis with poor recovery. She discontinued the medication only to start it again approximately two months later after which she then experienced painful vision loss in her right eye. Imaging performed on the right eye was consistent with NAION.

115. Despite the growing number of articles, reports and an investigation by the PRAC of the Danish Medicines Agency, the Defendant still provides no warnings about the dangerous side effect of NAION in conjunction with use of Ozempic.

116. On June 6, 2025, the European Medicines Agency (EMA) determined the product information should be updated to include the risk of NAION with a warning to patients that upon sudden vision loss or worsening vision, a physician should be contacted right away and the medication should be stopped if NAION is confirmed.⁹⁴

V. Defendant's Continuing Failure to Disclose the Risk of NAION

117. According to the Drugs@FDA website, the label for Ozempic has been updated on at least thirteen (13) occasions since 2017, with the most recent update on January 28, 2025.⁹⁵ Despite the fact there are at least fourteen (14) iterations of the Ozempic label, Defendant's labels

Semaglutide and Tirzepatide. *JAMA Ophthalmol.* Published online January 30, 2025.
doi:10.1001/jamaophthalmol.2024.6058

⁹³ *Id.*

⁹⁴ European Medicines Agency, PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (June 6, 2025), <https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy>

⁹⁵ See Drugs@FDA: FDA-Approved Drugs, Ozempic, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637> (last visited February 19, 2025).

have not contained any warning or any information whatsoever on the increased propensity of Ozempic to cause NAION and permanent vision loss as suffered by Plaintiff.

118. To date, the warning label is still devoid of any mention of NAION.

119. Furthermore, Defendant has failed to take any steps to otherwise warn the medical community, particularly physicians within the ophthalmologic community, to encourage a baseline eye exam prior to starting Ozempic, monitoring of patients while on the medication, and advising patients to cease use of the medication if they develop symptoms consistent with NAION or after the fact as to not risk the potential for injury in the other eye.

120. Nothing was or is stopping Defendant from adding a warning regarding the risk of NAION. Defendant could have at any time made “moderate changes” to the label.

121. Specifically, Defendant could have filed a “Changes Being Effected” (“CBE”) supplement under Section 314.70(c) of the FDCA to make “moderate changes” to Ozempic’s label without any prior FDA approval.

122. Examples of moderate label changes that can be made via a CBE supplement explicitly include changes “to reflect newly acquired information” in order to “add or strengthen a contraindication, warning, precaution, or adverse reaction.” By definition and by regulation such changes to add a warning based on newly acquired information—such as that imparted by newly emerging literature like the litany of studies cited above—are considered a “moderate change.” § 340.70(c)(6)(iii).

123. Recently, the Third Circuit reaffirmed that plain text interpretation of the CBE supplement process in a precedential decision holding that the defendant in that case, Merck, could not rely on a preemption defense based on an allegedly irreconcilable conflict between federal (FDCA) and state (civil tort) law so long as the warning could have been effected via a CBE

change. *See generally In re Fosamax (Alendronate Sodium) Prods. Liab. Litig.*, Case No. 22-3412, D.I. 82 at 73 on the docket (J. Jordan) (3d Cir. Sept. 20, 2024) (noting “the availability of a label change via a CBE supplement is problematic for Merck, as will very often be the case for pharmaceutical companies raising an impossibility defense”).

PLAINTIFF SPECIFIC FACTS

124. Upon information and belief, on or around May 01, 2023, Plaintiff was prescribed Ozempic to help manage his Type 2 diabetes.

125. At all times relevant, Defendant represented Ozempic to be appropriate, safe and suitable for such purposes.

126. On or around December 04, 2024, Plaintiff had an appointment with his ophthalmologist following sudden vision loss. Plaintiff’s doctor diagnosed him with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) in his right eye.

127. Plaintiff continued on Ozempic as prescribed until March 01, 2024.

128. Had Plaintiff been told his use of Ozempic was a substantial cause of development of NAION, he would have discontinued the medication right away. Instead, the package insert did not warn the medical community or patients of the risk of NAION, Plaintiff continued to inject Ozempic per the instructions and was not instructed to discontinue use even though he was also now at a higher risk of developing NAION in his left eye.

129. As a result of Defendant’s actions and inactions, Plaintiff suffers from permanent vision loss and seeks damages associated with these injuries.

130. Defendant knew or should have known that use of semaglutide could lead to severe and debilitating injuries suffered by Plaintiff and numerous other patients.

131. Defendant continues to downplay the risk of NAION and have not changed or provided any warnings to the public and medical community.

132. Defendant's Ozempic was at all times utilized and prescribed in a manner foreseeable to Defendant.

133. Plaintiff used Ozempic, and did not misuse, or alter Ozempic in an unforeseeable manner.

134. Through its affirmative misrepresentations and omissions, Defendant actively concealed from Plaintiff and his physicians the true and significant risks associated with this medication.

135. As a result of Defendant's actions, Plaintiff and his physicians were unaware, and could not have reasonably known or have learned through reasonable diligence, that Plaintiff would be exposed to the risks identified in this Complaint and that those risks were the direct and proximate result of Defendant's conduct.

136. As a direct result of being prescribed and using Ozempic, Plaintiff has been permanently and severely injured, having suffered serious consequences.

137. As a direct and proximate result of his Ozempic use, Plaintiff suffered severe mental and physical pain and suffering and has sustained permanent injuries and emotional distress, loss of earnings, loss of ability to earn money and other economic losses including past and future medical expenses.

138. Plaintiff diligently investigated the potential cause of these injuries, but their relationship to Ozempic was not discovered, and through reasonable care and diligence could not have been discovered, until a date within the applicable statute of limitations for filing Plaintiff's claims.

EQUITABLE TOLLING OF STATUTE OF LIMITATIONS

139. Defendant willfully, wantonly and intentionally conspired, and acted in concert, to withhold information from Plaintiff, Plaintiff's healthcare providers, and the general public concerning the known hazards associated with the use of Ozempic.

140. Defendant willfully, wantonly and intentionally conspired, and acted in concert, to withhold safety-related warnings from the Plaintiff, her family members, and the general public concerning the known hazards associated with the use of Ozempic.

141. Defendant willfully, wantonly and intentionally conspired, and acted in concert, to withhold instructions from the Plaintiff, her family members, and the general public concerning how to identify, mitigate, and/or treat known hazards associated with the use of Ozempic.

142. Defendant willfully, wantonly and intentionally conspired, and acted in concert, to ignore relevant safety concerns and to deliberately not study the risk of NAION associated with semaglutide.

143. Defendant failed to disclose a known defect and, instead, affirmatively misrepresent that Ozempic is safe for its intended use. Defendant disseminated labeling, marketing, promotion and/or sales information to Plaintiff, her healthcare providers, and the general public regarding the safety of Ozempic knowing such information was false, misleading, and/or inadequate to warn of the safety risks associated with Ozempic use. Defendant did so willfully, wantonly, and with the intent to prevent the dissemination of information known to them concerning Ozempic's safety.

144. Further, Defendant actively concealed the true risks associated with the use of Ozempic, particularly as they relate to the serious risk and permanent nature of NAION, by failing to include in numerous communications, which were disseminated to Plaintiff, her healthcare providers, and which included, without limitation, the Package Insert and the Medication Guide,

any warnings that Ozempic can cause injury to the optic nerve resulting in NAION and permanent vision loss.

145. Due to the absence of any warning by the Defendant as to the significant health and safety risks posed by Ozempic, Plaintiff was unaware that Ozempic could cause NAION, as this danger was not known to Plaintiff, Plaintiff's healthcare providers, or the general public.

146. Due to the absence of any instructions for how to identify and/or monitor Ozempic patients for the potential for NAION, Plaintiff was unaware that Ozempic could cause serious, vision-related injuries, as this danger was not known to Plaintiff, her healthcare providers or the general public.

147. Given Defendant's conduct and deliberate actions designed to deceive Plaintiff, Plaintiff's healthcare providers, and the general public, with respect to the safety and efficacy of Ozempic, Defendant is estopped from relying on any statute of limitations defenses.

COUNT I

STRICT LIABILITY – FAILURE TO WARN

N.J. Stat. § 2A:58C-2; Illinois Common Law; 735 Ill. Comp. Stat. Ann. § 5/2-2101 et seq.

148. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

149. At all relevant times, Defendant engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Ozempic and placed these drugs into the stream of commerce in a defective and unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendant.

150. Defendant as the holder of NDA is responsible for communications to the FDA and associated regulatory authorities, reporting of adverse events, label changes, post-market surveillance and pharmacovigilance.

151. Defendant, as a manufacturer, distributor, and marketer of pharmaceutical drugs, is held to the level of knowledge of an expert in the field, and further, Defendant knew or should have known that warnings and other clinically relevant information and data which they distributed regarding the risks associated with the use of Ozempic were inadequate.

152. Plaintiff did not have the same knowledge as Defendant and no adequate warning or other clinically relevant information, and data was communicated to Plaintiff or to Plaintiff's prescribing and treating physicians.

153. Defendant had a duty to provide adequate warnings and instructions for Ozempic, to use reasonable care to design a product that is not unreasonably dangerous to users, and to adequately understand, test, and monitor their products.

154. Defendant had a continuing duty to provide consumers, including Plaintiff and Plaintiff's physicians, with warnings and other clinically relevant information and data regarding the risks and dangers associated with Ozempic, as it became or could have become available to Defendant.

155. Defendant marketed, promoted, distributed and sold an unreasonably dangerous and defective prescription drugs, Ozempic, to health care providers empowered to prescribe and dispense Ozempic to consumers, including Plaintiff, without adequate warnings and other clinically relevant information and data. Through both omission and affirmative misstatements, Defendant misled and continues to mislead the medical community about the risk and benefit balance of Ozempic, which resulted in permanent injuries to Plaintiff.

156. Defendant knew or should have known through testing, scientific knowledge, advances in the field, or otherwise, that Ozempic created a risk of serious and potentially irreversible vision issues, sudden vision loss or blindness, severe optic nerve damage, and NAION in one or potentially both eyes.

157. Despite the fact that Defendant knew or should have known that Ozempic caused unreasonable and dangerous side effects, they continue to promote and market Ozempic without providing adequate clinically relevant information.

158. Defendant knew or should have known that consumers, Plaintiff, specifically, would foreseeably and needlessly suffer injury as a result of Defendant's failures.

159. The Ozempic supplied to Plaintiff by Defendant was defective, unreasonably dangerous, and had inadequate warnings or instructions at the time it was sold. Defendant possessed knowledge and information confirming the defective and unreasonably dangerous nature of Ozempic but despite this knowledge and information, Defendant failed and neglected to issue adequate warnings that Ozempic cause serious and potentially irreversible vision issues, optic nerve damage and NAION. Defendant has yet to issue any warnings or recommendations that patients taking Ozempic undergo ophthalmological monitoring.

160. Defendant's failure to provide adequate warnings or instructions rendered Ozempic unreasonably dangerous in that they failed to perform as safely as an ordinary patient, prescriber, and/or other consumer would expect when used as intended and/or in a manner reasonably foreseeable by the Defendant, and in that the risk of danger outweighs the benefits.

161. Defendant continues to fail to provide adequate warnings to physicians, pharmacies, and consumers, including Plaintiff and to Plaintiff's intermediary physicians.

162. Defendant failed to include adequate warnings and/or provide adequate clinically relevant information and data that would alert Plaintiff and Plaintiff's physicians to the dangerous risks of Ozempic including, among other things, potentially irreversible vision issues such as NAION and optic nerve damage.

163. Defendant failed to provide adequate post-marketing warnings and instructions after Defendant knew or should have known of the significant risks of, among other things, potentially irreversible vision issues and optic nerve damage.

164. Defendant continued to aggressively promote and sell Ozempic, even after they knew or should have known of the unreasonable risks of potentially irreversible vision issues and optic nerve damage from the drugs.

165. Defendant had an obligation to provide Plaintiff and Plaintiff's physicians with adequate clinically relevant information and data and warnings regarding the adverse health risks associated with exposure to Ozempic and/or that there existed safer and or equally effective alternative drug products that do not pose this same risk.

166. By failing to adequately test and research harms associated with Ozempic, and by failing to provide appropriate warnings and instructions about use, patients and the medical community, including prescribing doctors, were inadequately informed about the true risk-benefit profile of Ozempic and were not sufficiently aware that serious and potentially irreversible vision issues and optic nerve damage might be associated with use of Ozempic. Nor were the medical community, patients, patients' families, or regulators appropriately informed that serious and potentially irreversible vision issues and optic nerve damage might be a side effect of Ozempic and should or could be reported as an adverse event.

167. The semaglutide products designed, researched, manufactured, tested, advertised, promoted, marketed, sold and distributed by Defendant were defective due to inadequate post-marketing surveillance and/or warnings because, even after Defendant knew or should have known of the risks of severe and permanent vision loss and optic nerve injuries from using Ozempic, Defendant failed to provide adequate warnings to users or consumers of the products, and continued to improperly advertise, market and/or promote .

168. Ozempic are defective and unreasonably dangerous to Plaintiff and other consumers regardless of whether Defendant had exercised all possible care in their preparation and sale.

169. The foreseeable risk of serious and potentially irreversible vision issues and harm to the optic nerve caused by Ozempic could have been reduced or avoided by Plaintiff, prescribers, and/or other consumers had Defendant provided reasonable instructions or warnings of these foreseeable risks of harm.

170. As a direct and proximate result of Defendant's conduct, including the inadequate warnings, lack of information, lack of adequate testing and research, and the defective and dangerous nature of Ozempic, Plaintiff suffered bodily injuries and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses, and aggravation of previously existing conditions. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT II
STRICT LIABILITY – DESIGN DEFECT
N.J. Stat. § 2A:58C-2; Illinois Common Law; 735 Ill. Comp. Stat. Ann. § 5/2-2101 et seq.

171. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

172. At all relevant times, Defendant engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Ozempic and placed these drugs into the stream of commerce in a defective and unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendant.

173. Defendant as the holder of NDA is responsible for communications to the FDA and associated regulatory authorities, reporting of adverse events, label changes, post-market surveillance and pharmacovigilance.

174. Defendant, as a manufacturer, designer, distributor, and marketer of pharmaceutical drugs, had a duty to design a product free from a defective condition that was unreasonably dangerous to the Plaintiff.

175. Ozempic were designed in such a way that posed an unreasonable risk of permanent vision loss and optic nerve injuries and were kept on the market despite being in a defective condition.

176. Defendant knew or should have known the Ozempic they developed, manufactured, labeled, marketed, sold, and/or promoted were defectively designed in that they posed a serious risk of severe and permanent vision and optic nerve injuries.

177. Defendant had a continuing duty to design a product that is not unreasonably dangerous to users and to adequately understand, test, and monitor their product.

178. Defendant sold, marketed and distributed products that are unreasonably dangerous for their normal, intended, and foreseeable use.

179. Defendant designed, researched, manufactured, tested, advertised, promoted, marketed, sold and distributed Ozempic, defective products which created an unreasonable risk to the health of consumers, and Defendant is therefore strictly liable for the injuries sustained by Plaintiff.

180. The Ozempic supplied to Plaintiff by Defendant was defective in design or formulation in that, when it left the hands of the manufacturer or supplier, it was in an unreasonably dangerous and a defective condition because it failed to perform as safely as an ordinary consumer would expect when used as intended or in a manner reasonably foreseeable to Defendant, posing a risk of serious and potentially irreversible vision issues and optic nerve damage to Plaintiff and other consumers.

181. The Ozempic taken by Plaintiff was expected to, and did, reach Plaintiff without substantial change in the condition in which it is sold.

182. The Ozempic taken by Plaintiff was in a condition not contemplated by the Plaintiff in that it was unreasonably dangerous, posing a serious risk of permanent vision loss and optic nerve damage.

183. Ozempic is a medication indicated for treatment of type 2 diabetes but is often prescribed for weight loss as well. Ozempic in fact causes serious and potentially irreversible vision issues, severe optic nerve damage, sudden blindness and NAION in one or both eyes, harming Plaintiff and other consumers.

184. Plaintiff, ordinary consumers, and prescribers would not expect a diabetes drug designed and marketed for all of its supposed health benefits, including weight loss, to cause irreversible vision issues and optic nerve damage.

185. The Ozempic supplied to Plaintiff by Defendant was defective in design or formulation in that, when it left the hands of the manufacturer or supplier, it had not been adequately tested, was in an unreasonably dangerous and defective condition, and posed a risk of serious and potentially irreversible vision issues and optic nerve damage to Plaintiff and other consumers.

186. The Ozempic supplied to Plaintiff by Defendant was defective in design or formulation in that its alleged benefits did not outweigh the risks of serious and potentially irreversible vision issues and optic nerve damage posed by the drug. In light of the utility of the drug and the risk involved in its use, the design of Ozempic makes the product unreasonably dangerous.

187. Ozempic's design is more dangerous than a reasonably prudent consumer would expect when used in its intended or reasonably foreseeable manner. It was more dangerous than Plaintiff expected.

188. The intended or actual utility of Ozempic is not of such benefit to justify the risk of optic nerve damage that may be irreversible and permanently disabling thereby rendering the product unreasonably dangerous.

189. The design defects render Ozempic more dangerous than other drugs and therapies designed to treat type 2 diabetes and obesity and cause an unreasonable increased risk of injury, including, but not limited, to potentially irreversible vision issues and optic nerve damage.

190. Defendant knew or should have known through testing, scientific knowledge, advances in the field, or otherwise, that Ozempic created a risk of serious and potentially irreversible vision issues, severe optic nerve damage, sudden blindness, and NAION in one or both eyes.

191. Ozempic is defective and unreasonably dangerous to Plaintiff and other consumers in that, despite knowledge that Ozempic use could result in vision issues, Defendant failed to adequately test or study the drugs, including but not limited to: pharmacokinetics and pharmacodynamics of the drugs, its effects on vision and the optic disc, the potential for inter-patient variability, and/or the potential for a safer effective dosing regimen.

192. Defendant acted unreasonably in its design of Ozempic in that Defendant failed to adopt a safer design for the product that was practical, feasible, and otherwise a reasonable alternative design or formulation that would have prevented or substantially reduced the risk of harm without substantially impairing the usefulness, practicality, or desirability of the product.

193. Defendant knew or should have known that consumers, and Plaintiff specifically, would foreseeably and needlessly suffer injury as a result of Ozempic's defective design.

194. Ozempic are defective and unreasonably dangerous to Plaintiff and other consumers even if Defendant had exercised all possible care in the preparation and sale of these products.

195. As a direct and proximate result of Defendant's conduct, including the inadequate warnings, lack of adequate testing and research, and the defective and dangerous nature of Ozempic, Plaintiff suffered bodily injuries and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses, and aggravation of previously existing conditions. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT III
NEGLIGENT FAILURE TO WARN
Illinois Common Law; 735 Ill. Comp. Stat. Ann. § 5/2-2101 et seq.

196. Plaintiff incorporates by reference each allegation set forth in preceding paragraphs as if fully stated herein.

197. At all relevant times, Defendant engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Ozempic and placed these drugs into the stream of commerce in a defective and unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendant.

198. Defendant as the holder of NDA is responsible for communications to the FDA and associated regulatory authorities, reporting of adverse events, label changes, post-market surveillance and pharmacovigilance.

199. Ozempic was expected to reach, and did reach, users and/or consumers, including Plaintiff, without substantial change in the defective and unreasonably dangerous condition in which it was sold or distributed.

200. Defendant owed Plaintiff and other Ozempic users a duty to exercise reasonable care in marketing, advertising, promoting, distributing and/or selling Ozempic.

201. At all times material, Ozempic was used in a manner intended and/or foreseeable to Defendant.

202. A reasonable patient or consumer of Ozempic would expect the drug to be free of significant defects.

203. Defendant knew or had reason to know of facts establishing that Ozempic could cause NAION and failed to warn of the risk.

204. At all times relevant hereto, the defective nature of Ozempic was known to Defendant, or reasonably and scientifically knowable to them, through appropriate research and testing by known methods, at the time they distributed, supplied, or sold Ozempic, and not known to ordinary physicians who would be expected to prescribe the drug to their patients.

205. In disregard of its duty to timely warn consumers of health risks associated with Ozempic, Defendant committed one or more of the following negligent acts or omissions:

- a. Failing to properly and adequately warn and instruct Plaintiff and Plaintiff's treating physicians that Ozempic was designed and/or manufactured in a way that it could cause injuries and damages, including permanent vision loss;
- b. Failing to timely disclose to Plaintiff and Plaintiff's prescribing and treating physicians the risk of NAION;
- c. Failing to timely warn Plaintiff and Plaintiff's physicians that a base line eye exam should be performed and monitoring was necessary.

206. At all relevant times, the label for Ozempic was inadequate because it did not warn and/or adequately warn of all possible adverse side effect of NAION and permanent vision loss.

207. At all relevant times, the label for Ozempic was inadequate because it did not warn and/or adequately warn that Ozempic had not been sufficiently and/or adequately tested for safety risks, including NAION.

208. The labels for Ozempic were inadequate because they did not warn and/or adequately warn of all possible adverse side effects concerning the failure and/or malfunction of Ozempic.

209. Defendant's failure to warn of the above was the proximate cause of Plaintiff's injuries, harm, and economic loss, from which Plaintiff continue to suffer.

210. Defendant's failure to warn of the significant risks of Ozempic use prevented Plaintiff and Plaintiff's treating physicians from conducting a proper assessment of the risks and benefits of using Ozempic.

211. Had Plaintiff and/or Plaintiff's treating physicians been properly warned of the significant risks of Ozempic, she would not have elected to begin and/or continue Ozempic.

212. Reasonable, safer alternative treatments were available to Plaintiff and/or Plaintiff's treating physicians had they been warned of these significant risks.

213. As a direct and proximate result of Defendant's conduct, including the inadequate warnings, lack of adequate testing and research, and the defective and dangerous nature of Ozempic, Plaintiff suffered bodily injuries and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses, and aggravation of previously existing conditions. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT IV
NEGLIGENCE

Illinois Common Law; 735 Ill. Comp. Stat. Ann. § 5/2-2101 et seq.

214. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

215. At all relevant times, Defendant engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Ozempic and placed these drugs into the stream of commerce in a defective and

unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendant.

216. Defendant as the holder of NDA is responsible for communications to the FDA and associated regulatory authorities, reporting of adverse events, label changes, post-market surveillance and pharmacovigilance.

217. At all times relevant hereto, it was the duty of Defendant to use reasonable care in the design, labeling, manufacturing, testing, marketing, distribution and/or sale of Ozempic.

218. Defendant failed to exercise ordinary care in the labeling, design, manufacturing, testing, marketing, distribution and/or sale of Ozempic in that Defendant knew or should have known these drugs created a high risk of unreasonable harm to Plaintiff and other users.

219. Defendant had no reason to believe that intended and foreseeable users of Ozempic, such as Plaintiff, would realize the potential harms from use of these products.

220. Defendant failed to exercise reasonable care to inform users, such as Plaintiff, of Ozempic's risk of serious and potentially irreversible vision issues and harm to the optic nerve.

221. Defendant breached its duty of care to the Plaintiff and her physicians, in the testing, monitoring, and pharmacovigilance of Ozempic.

222. In disregard of its duty, Defendant committed one or more of the following negligent acts or omissions:

- a. Manufacturing, producing, promoting, formulating, creating, developing, designing, selling, and distributing Ozempic without thorough and adequate pre- and post-market testing of the products;
- b. Manufacturing, producing, promoting, advertising, formulating, creating, developing, and designing, and distributing Ozempic while negligently and intentionally concealing and failing to disclose clinical data which demonstrated the risk of serious harm associated with the use of Ozempic;

- c. Failing to undertake sufficient studies and conduct necessary tests to determine whether or not Ozempic were safe for their intended use;
- d. Failing to disclose and warn of the product defect to the medical community, and consumers that Defendant knew and had reason to know that Ozempic were indeed unreasonably unsafe and unfit for use by reason of the product defects and risk of harm to its users;
- e. Failing to warn Plaintiff, the medical and healthcare community, and consumers that the Ozempic's risk of harm was unreasonable and that there were safer and effective alternative products available to Plaintiff and other consumers;
- f. Failing to provide adequate instructions, guidelines, and safety precautions to those persons to whom it was reasonably foreseeable would use Ozempic;
- g. Advertising, marketing, and recommending the use of Ozempic, while concealing and failing to disclose or warn of the dangers known by Defendant to be connected with, and inherent in, the use of these products;
- h. Representing that Ozempic were safe for their intended use when in fact Defendant knew and should have known the products were not safe for their intended purpose;
- i. Continuing to manufacture and sell Ozempic with the knowledge that Ozempic are unreasonably unsafe and dangerous;
- j. Failing to use reasonable and prudent care in the design, research, testing, manufacture, and development of Ozempic so as to avoid the risk of serious harm associated with the use of semaglutide. Failing to design and manufacture Ozempic so as to ensure these drugs were at least as safe and effective as other similar products;
- k. Failing to design and manufacture Ozempic reasonably safe for their intended purpose in violation of objective safety standards;
- l. Failing to ensure the product was accompanied by proper and accurate warnings about requiring baseline visual examinations and regular eye examinations while using the drug;
- m. Failing to ensure the product was accompanied by proper and accurate warnings about possible adverse side effects associated with the use of Ozempic and that use of semaglutide created a high risk of severe, permanent injuries to vision; and

- n. Failing to conduct adequate testing, including pre-clinical and clinical testing, and post-marketing surveillance to determine the safety of Ozempic.

223. A reasonable manufacturer, designer, distributor, promotor, or seller under the same or similar circumstances would not have engaged in the aforementioned acts and omissions.

224. As a direct and proximate result of the Defendant's negligent testing, monitoring, and pharmacovigilance of Ozempic, Defendant introduced products they knew or should have known would cause injury to the optic nerve, NAION and resulting serious and permanent injuries to an individual's vision, and Plaintiff has been injured catastrophically and sustained severe and permanent pain, suffering, disability, and impairment, loss of enjoyment of life, loss of care, comfort, and economic damages.

225. As a direct and proximate result of Defendant's conduct, including the inadequate warnings, lack of adequate testing and research, and the defective and dangerous nature of Ozempic, Plaintiff suffered bodily injuries and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses, and aggravation of previously existing conditions. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT V
NEGLIGENT MISREPRESENTATION
Illinois Common Law; 735 Ill. Comp. Stat. Ann. § 5/2-2101 et seq.

226. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

227. At all relevant times, Defendant engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Ozempic and placed these drugs into the stream of commerce in a defective and unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendant.

228. Defendant as the holder of NDA is responsible for communications to the FDA and associated regulatory authorities, reporting of adverse events, label changes, post-market surveillance and pharmacovigilance.

229. At all relevant times, Defendant negligently provided Plaintiff, her healthcare providers, and the general medical community with false or incorrect information or omitted or failed to disclose material information concerning Ozempic, including, but not limited to, misrepresentations regarding the safety and known risks of Ozempic.

230. The information distributed by the Defendant to the public, the medical community, Plaintiff and her healthcare providers, including advertising campaigns, labeling materials, print advertisements, commercial media, was false and misleading and contained omissions and concealment of truth about the dangers of Ozempic.

231. Defendant's intent and purpose in making these misrepresentations was to deceive and defraud the public and the medical community, including Plaintiff and Plaintiff's health care providers; to falsely assure them of the quality of Ozempic and induce the public and medical community, including Plaintiff and her healthcare provider to request, recommend, purchase, and prescribe Ozempic.

232. Defendant had a duty to accurately and truthfully represent to the medical and healthcare community, Plaintiff, her healthcare providers and the public, the known risks of

Ozempic, including its propensity to cause permanent vision loss, NAION and injury to the optic nerve.

233. Defendant made continued omissions in the Ozempic labeling, including promoting it as safe and effective while failing to warn of its propensity to cause permanent vision loss, NAION and injury to the optic nerve.

234. Defendant made additional misrepresentations beyond the product labeling by representing Ozempic as a safe and effective treatment for type 2 diabetes and weight loss with only minimal risks.

235. Defendant misrepresented and overstated the benefits of Ozempic to Plaintiff, Plaintiff's treaters, and the medical community without properly advising of the known risks to permanent vision loss.

236. In reliance upon the false and negligent misrepresentations and omissions made by the Defendant, Plaintiff and Plaintiff's healthcare providers were induced to, and did use Ozempic, thereby causing Plaintiff to endure severe and permanent injuries.

237. In reliance upon the false and negligent misrepresentations and omissions made by the Defendant, Plaintiff and Plaintiff's healthcare providers were unable to associate the injuries sustained by Plaintiff with her Ozempic use before it was too late. Defendant knew or should have known that the Plaintiff, Plaintiff's healthcare providers, and the general medical community did not have the ability to determine the true facts which were intentionally and/or negligently concealed and misrepresented by the Defendant.

238. Plaintiff and her healthcare providers would not have used or prescribed Ozempic had the true facts not been concealed by the Defendant.

239. Defendant had sole access to many of the material facts concerning the defective nature of Ozempic and its propensity to cause serious and dangerous side effects.

240. At the time Plaintiff was prescribed and administered Ozempic, Plaintiff and her healthcare providers were unaware of Defendant's negligent misrepresentations and omissions.

241. The Defendant failed to exercise ordinary care in making representations concerning Ozempic while they were involved in their manufacture, design, sale, testing, quality assurance, quality control, promotion, marketing, labeling, and distribution in interstate commerce, because the Defendant negligently misrepresented Ozempic's risk of unreasonable and dangerous adverse side effects.

242. Plaintiff and Plaintiff's healthcare providers reasonably relied upon the misrepresentations and omissions made by the Defendant, where the concealed and misrepresented facts were critical to understanding the true dangers inherent in the use of the Ozempic.

243. Plaintiff and Plaintiff's healthcare providers' reliance on the foregoing misrepresentations and omissions was the direct and proximate cause of Plaintiff's injuries.

244. As a direct and proximate result of reliance upon Defendant's negligent misrepresentations, Plaintiff suffered bodily injury and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT VI
BREACH OF EXPRESS WARRANTY
N.J. Stat. Ann. § 12A:2-101 et seq.
810 Ill. Comp. Stat. Ann. § 5/2-313 et seq.

245. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

246. At all relevant times, Defendant engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Ozempic, and placed them into the stream of commerce in a defective and unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendant.

247. Defendant as the holder of NDA is responsible for communications to the FDA and associated regulatory authorities, reporting of adverse events, label changes, post-market surveillance and pharmacovigilance.

248. Defendant expressly warranted to Plaintiff, Plaintiff's healthcare providers, and the general public, by and through Defendant and/or its authorized agents or sales representatives, in publications, labeling, the internet, and other communications intended for physicians, patients, Plaintiff, and the general public, that Ozempic were safe, effective, fit and proper for their intended use.

249. Ozempic materially failed to conform to those representations made by Defendant, in package inserts and otherwise, concerning the properties and effects of Ozempic, which Plaintiff purchased and injected in direct or indirect reliance upon these express representations. Such failures by Defendant constituted a material breach of express warranties made, directly or indirectly, to Plaintiff concerning Ozempic sold to Plaintiff.

250. Defendant expressly warranted that Ozempic were safe and well-tolerated. However, Defendant did not have adequate proof upon which to base such representations, and, in fact, knew or should have known that Ozempic were particularly dangerous to the well-being of Plaintiff and

Plaintiff's vision.

251. Ozempic do not conform to those express representations because they are defective, not safe, and have serious adverse side effects.

252. Plaintiff and Plaintiff's physicians justifiably relied on Defendant's representations regarding the safety of Ozempic, and Defendant's representations became part of the basis of the bargain.

253. Plaintiff and Plaintiff's healthcare providers justifiably relied on Defendant's representations that Ozempic was safe and well-tolerated in their decision to ultimately prescribe, purchase and use the drug.

254. Plaintiff's healthcare providers justifiably relied on Defendant's representations through Defendant's marketing and sales representatives in deciding to prescribe Ozempic over other alternative treatments on the market, and Plaintiff justifiably relied on Defendant's representations in deciding to purchase and use the drug.

255. Plaintiff purchased and used Ozempic without knowing that drug is not safe and well-tolerated, but that Ozempic instead causes significant and irreparable vision loss and eye damage.

256. As a direct and proximate result of Defendant's conduct, including the inadequate warnings, lack of adequate testing and research, and the defective and dangerous nature of Ozempic, Plaintiff suffered bodily injuries and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses, and aggravation of previously existing conditions. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT VII
BREACH OF IMPLIED WARRANTY
810 Ill. Comp. Stat. Ann. § 5/2-314 et seq.; 810 Ill. Comp. Stat. Ann. § 5/2-315 et seq.

257. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

258. At all relevant times, Defendant engaged in the business of researching, testing, developing, manufacturing, labeling, marketing, selling, inspecting, handling, storing, distributing, and/or promoting Ozempic, and placed it into the stream of commerce in a defective and unreasonably dangerous condition. These actions were under the ultimate control and supervision of Defendant.

259. Defendant as the holder of NDA is responsible for communications to the FDA and associated regulatory authorities, reporting of adverse events, label changes, post-market surveillance and pharmacovigilance.

260. Defendant was the seller of Ozempic and sold Ozempic to be taken for treatment of type 2 diabetes and weight loss.

261. When the Ozempic was prescribed by Plaintiff's physician and taken by Plaintiff, the product was being prescribed and used for the ordinary purpose for which it was intended.

262. Defendant impliedly warranted their product, which they manufactured and/or distributed and sold, and which Plaintiff purchased and used, to be of merchantable quality and fit for the common, ordinary, and intended uses for which the product was sold.

263. Defendant breached their implied warranties of the Ozempic product because the Ozempic sold to Plaintiff was not fit for its ordinary purpose to treat type 2 diabetes and help with

weight loss safely and effectively.

264. The Ozempic would not pass without objection in the trade; they are not of fair average quality; they are not fit for their ordinary purposes for which the products are used; were not adequately contained, packaged and labeled; and fail to conform to the promises or affirmations of fact made on the container or label.

265. Defendant's breach of their implied warranties resulted in use of the unreasonably dangerous and a defective product by Plaintiff, which placed Plaintiff's health and safety at risk and resulted in the damages alleged herein.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT VIII
CONSUMER FRAUD ACT
N.J.S.A. 56:8 et seq.

266. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

267. Plaintiff purchased and used Ozempic primarily for personal use and therefore suffered ascertainable losses as a result of Defendant's actions in violation of N.J.S.A. 56:8 *et seq.*

268. Had Defendant not made affirmative misrepresentations, material omissions, and engaged in the deceptive conduct described herein, Plaintiff would not have purchased Ozempic and would not have incurred damages.

269. Defendant engaged in wrongful conduct while at the same time obtaining, under false pretenses, money from Plaintiff that would not have been paid had Defendant not engaged in unfair and deceptive conduct.

270. Despite knowing the falsity and misleading nature of their claims, Defendant

engaged in unconscionable commercial practices, deception, fraud, false promise, misrepresentation and/or the knowing concealment, suppression or omission of material facts relative to the safety and efficacy of Ozempic.

271. Defendant intended such actions to mislead patients, healthcare providers, and the general public with respect to the safety and efficacy of Ozempic.

272. Such actions did, in fact, mislead patients, healthcare providers, and the general public with respect to the safety and efficacy of Ozempic.

273. Defendant had a statutory duty to refrain from unfair or deceptive acts or trade practices in the design, labeling, development, manufacture, promotion, and sale of Ozempic.

274. Defendant's deceptive, unconscionable, or fraudulent representations and material omissions to patients, physicians and consumers, including Plaintiff Gloria Perkins constituted unfair and deceptive acts and trade practices in violation of N.J.S.A. 56:8 *et seq.*

275. As a direct and proximate result of Defendant's conduct, including the inadequate warnings, dilution or lack of information, lack of adequate testing and research, and the defective and dangerous nature of Ozempic, Plaintiff Gloria Perkins suffered bodily injuries and resulting pain and suffering, disability, mental anguish, loss of capacity for the enjoyment of life, expense of medical and nursing care and treatment, loss of earnings, loss of ability to earn money and other economic losses, and aggravation of previously existing conditions. The losses are either permanent or continuing, and Plaintiff will suffer the losses in the future.

WHEREFORE, Plaintiff respectfully requests that Plaintiff be granted relief against Defendant, as contained in the Prayer For Relief.

COUNT IX
PUNITIVE DAMAGES ACT (N.J.S.A. 2A:15-5.9, et seq.)

276. Plaintiff incorporates by reference each and every preceding paragraph as though

fully set forth herein.

277. The acts and omissions of Defendant described herein consisted of oppression, fraud, and/or malice, and were done with advance knowledge, conscious disregard of the safety of others, and/or ratification by Defendant's officers, directors, and/or managing agents.

278. Defendant's actions amounted to actual malice or reckless indifference to the likelihood of harm associated with their acts and omissions.

279. Defendant misled both the medical community and the public, including Plaintiff and her physicians, by making false representations about the safety and effectiveness of Ozempic and by failing to provide adequate instructions concerning its use.

280. Defendant downplayed, understated, and/or disregarded their knowledge of the serious and permanent side effects and risks associated with the use of Ozempic despite available information demonstrating that drug could cause NAION and irreversible vision loss.

281. Defendant was or should have been in possession of evidence demonstrating that Ozempic use could cause NAION and irreversible vision loss. Nevertheless, Defendant continues to market Ozempic by providing false and misleading information with regard to their safety and effectiveness.

282. Defendant failed to provide warnings that would have dissuaded health care professionals from using Ozempic, thus preventing health care professionals, including Plaintiff's prescribing physician, and consumers, including Plaintiff, from weighing the true risks against the benefits of using Ozempic.

283. As a proximate result of Defendant's acts and omissions, Plaintiff was diagnosed with NAION and suffers from irreparable vision loss due to her use of Ozempic.

284. As a result of Plaintiff's injuries, Plaintiff has endured substantial pain and suffering,

has incurred significant expenses for medical care, and will remain economically challenged and emotionally harmed.

285. Plaintiff has suffered and will continue to suffer economic loss and has otherwise been emotionally and economically injured.

286. Defendant's actions were performed willfully, intentionally, and with reckless disregard for the rights of Plaintiff and the public.

287. Plaintiff's injuries and damages are severe, permanent and will continue into the future. As a result, Plaintiff seeks actual and punitive damages from the Defendant.

288. Defendant's conduct was committed with knowing, conscious and deliberate disregard for the rights and safety of consumers, including Plaintiff, thereby entitling Plaintiff to punitive damages in an amount appropriate to punish the Defendant and deter them from similar conduct in the future.

289. Consequently, Defendant is liable for punitive damages in an amount to be determined by the jury.

COUNT X
LOSS OF CONSORTIUM
(735 ILCS 5/13-203)

290. Plaintiff incorporates by reference each and every preceding paragraph as though fully set forth herein.

291. Plaintiff, JEROME FINNIGAN, is, and at all relevant times was, the lawful spouse of JANE FINNIGAN.

292. Plaintiffs were lawfully married prior to the occurrence described in Count IV and remain married.

293. As a direct and proximate result of Defendant's negligent conduct described in

Count IV, JEROME FINNIGAN sustained severe and permanent injuries.

294. That as a result of the wrongful and negligent acts of the Defendants, and each of them, the Plaintiffs were caused to suffer, and will continue to suffer in the future, loss of consortium, loss of society, affection, assistance, and conjugal fellowship, all to the detriment of their marital relationship.

WHEREFORE, Plaintiff(s) respectfully requests that Plaintiff(s) be granted relief against Defendant, as contained in the Prayer For Relief.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff(s) prays for judgment against the Defendant as follows:

- a. Awarding compensatory damages;
- b. Awarding actual damages to the Plaintiff(s) incidental to Plaintiff(s) purchase and use of Ozempic in an amount to be determined at trial;
- c. Awarding punitive damages to the Plaintiff(s);
- d. Awarding pre-judgment and post-judgment interest to the Plaintiff(s);
- e. Awarding the costs and the expenses of their litigation to the Plaintiff(s);
- f. Awarding reasonable attorneys' fees and costs to Plaintiff(s) as provided by law; and
- g. Granting all such other relief as the Court deems necessary, just and proper.

MOLL LAW GROUP

Date: March 4, 2026

By: /s/ Ken Moll
Ken Moll (IL SBN #6199874)
180 N. Stetson Ave. 35th Floor
Chicago, IL 60601
P: 312.462.1700
F: 312.756.0045
info@molllawgroup.com

Attorneys for Plaintiff

DEMAND FOR JURY TRIAL

Demand is hereby made for a trial by jury.

MOLL LAW GROUP

Date: March 4, 2026

By: /s/ Ken Moll
Ken Moll (IL SBN #6199874)
180 N. Stetson Ave. 35th Floor
Chicago, IL 60601
P: 312.462.1700
F: 312.756.0045
info@molllawgroup.com

Attorneys for Plaintiff

CERTIFICATION PURSUANT TO RULE 4:5-1

The undersigned attorney for Plaintiff certifies as follows:

1. The matter in controversy is not the subject of any other action pending in any Court or of a pending arbitration proceeding;
2. No other action or arbitration proceeding is contemplated; and
3. There are no known parties who may be liable to any party on the basis of the transaction or events which form the subject matter of their action that should be joined pursuant to R. 4:28.

I certify that the foregoing statements made by me are true to the best of my knowledge, information and belief. I am aware that if any of the foregoing statements made by me are willfully false, I am subject to punishment.

Respectfully submitted,

MOLL LAW GROUP

Date: March 4, 2026

By: /s/ Ken Moll

Ken Moll (IL SBN# 6199874)

180 N. Stetson Ave. 35th Floor

Chicago, IL 60601

P: 312.462.1700

F: 312.756.0045

info@molllawgroup.com

Attorneys for Plaintiff